Ilene Weitz, MD is a Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). She practices at LAC+USC Medical Center, Keck Hospital of USC, and USC Norris Cancer Hospital. Ilene Weitz, MD is board-certified in Internal Medicine and Hematology. She earned her medical degree from the Medical College of Pennsylvania in Philadelphia, completed her internship and residency in internal medicine at Cedars-Sinai Medical Center, and pursued a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California. Ilene Weitz, MD's clinical and research interests encompass a range of hematologic disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), cold agglutinin disease, thrombotic microangiopathies (TMA), sickle cell disease, thalassemia, and immune-mediated anemias and thrombocytopenia. She has contributed to numerous publications in journals such as the American Journal of Hematology, Journal of Clinical Oncology, and Hepatology, and has authored several book chapters and reviews. A dedicated educator, Ilene Weitz, MD has been recognized with the Morris Press Humanism Award and the Golden Apple Outstanding Physician Educator Award from Cedars-Sinai Medical Center. She has also received the Outstanding Voluntary Faculty Award in the Division of Hematology from USC School of Medicine. Ilene Weitz, MD continues to advance the field of hematology through her clinical practice, research, and commitment to medical education.

Daniel H. Wiseman, MBChB, PhD is an Honorary Consultant Haematologist at The Christie NHS Foundation Trust and a Senior Clinical Lecturer at The University of Manchester, where he leads an internationally recognized research program in myeloid malignancies. He is a leading expert in the diagnosis, management, and translational study of chronic myelomonocytic leukemia (CMML) and related myeloid neoplasms. Dr. Wiseman completed his medical education at The University of Manchester, earning his MBChB in 2003, followed by specialist training in hematology and a PhD in Cancer Sciences from The University of Manchester in 2016. Dr. Wiseman specializes in the care of patients with myeloid malignancies, with particular expertise in CMML, myelodysplastic syndromes (MDS), MDS/MPN overlap syndromes, and acute myeloid leukemia (AML). His clinical work integrates emerging molecular diagnostics with evolving therapeutic strategies, including allogeneic hematopoietic cell transplantation for high-risk disease. His research program focuses on the molecular pathogenesis of CMML and related neoplasms through integrative multi-omic approaches, with emphasis on epigenetics, RNA splicing dysregulation, and monocyte/macrophage biology. He has played a key role in characterizing the molecular and immunologic heterogeneity of CMML and currently serves as Co-Investigator on a translational program developing peptide-drug conjugates as novel targeted therapies for CMML. Dr. Wiseman contributes to international collaborations advancing care for patients with myeloid malignancies, including EBMT consensus recommendations on allogeneic transplantation in MDS/MPN overlap syndromes. His contributions have been recognized through honors including the ASH/EHA Translational Research Training in Haematology Fellowship and the Dexter Award.

Post ASCO 2026 Updates is an expert led session focused on high level clinical updates emerging from the 2026 American Society of Clinical Oncology Annual Meeting. The discussion will be organized by disease category and clinical domain, with each faculty member reviewing recent data through the lens of their subspecialty expertise and its potential relevance to patient care. Plasma cell disorders and monoclonal gammopathies will be discussed by Adeel Khan, MD, Assistant Professor of Internal Medicine in the Division of Hematology and Oncology at UT Southwestern Medical Center. This portion of the session will broadly address clinical updates relevant to multiple myeloma, amyloidosis, and related precursor states, with emphasis on evolving approaches to disease assessment and management. Bone marrow failure syndromes and clonal cytopenias will be covered by Taha Bat, MD, Assistant Professor of Internal Medicine at UT Southwestern. His segment will focus on recent clinical developments applicable to marrow based disorders, highlighting how emerging evidence may inform diagnostic evaluation and therapeutic decision making in patients with complex cytopenias. Leukemia related updates will be presented by Moaath Mustafa Ali, MD, MPH, hematologist and medical oncologist at Cleveland Clinic specializing in leukemia and related hematologic malignancies. He is board certified in internal medicine, hematology, and medical oncology. With training in clinical medicine and public health, his work focuses on leukemia care, transplantation outcomes, and clinical research. His segment will review selected clinical developments across acute and chronic leukemias, with attention to evolving therapeutic strategies and their potential implications for patient care. Lymphoma and cellular therapy related updates will be presented by Elif Yilmaz, MD, Assistant Professor of Internal Medicine at UT Southwestern. This section will review selected clinical updates relevant to indolent and aggressive lymphomas, with attention to evolving treatment strategies and integration of novel therapies. Together, these categorical discussions will provide a concise overview of Post ASCO 2026 clinical updates across major hematologic disease areas, emphasizing interpretation of new evidence within real world clinical practice.